Argenx reports half year 2025 financial results and provides second quarter business update

$949 million in second quarter global product net sales vyvgart sc launch in cidp progresses with more than 2,500 patients on treatment globally argx-119 to advance to registrational study in cms following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 management to host conference call today at 2:30 pm cet (8:30 am et) july 31, 2025 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business update. “we continue to make meaningful progress towards our vision 2030, advancing bold innovation that has already reached more than 15,000 patients globally” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking